Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Nivolumab
Indication/Tumor Type renal cell carcinoma
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive renal cell carcinoma predicted - sensitive Nivolumab Phase II Actionable In a Phase II trial (HCRN GU16-260), Opdivo (nivolumab) treatment in patients with CD274 (PD-L1)-positive treatment-naive advanced clear cell renal cell carcinoma resulted in an objective response rate (ORR) 50% (8/16) in patients with CD274 (PD-L1) expression between 1% to 20% and an ORR of 75% (6/8), median progression-free survival (PFS) of 20.6 months, and 1-year PFS rate of 75% in patients with CD274 (PD-L1) expression of 20% or higher (PMID: 35442713; NCT03117309). 35442713
PubMed Id Reference Title Details
(35442713) Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). Full reference...